Positive Phase II Study Data Suggest ARAKODA® (tafenoquine) Numerically Improved Clinical Recovery in Patients with Mild-Moderate COVID-19 Disease
LEARN MORE
Developing therapeutic innovations that can significantly improve and extend people’s lives.
In 2010, 60° Pharmaceuticals began its mission to build a better world by undertaking research and action focused on aiding in the prevention of infectious diseases. In 2022, we are continuing this mission with a broader focus on product development and commercialization for infectious diseases.
Finding solutions to enhance response to COVID-19 infections
We are advancing clinical trials for a therapy that may potentially accelerate symptom relief.
Escalating malaria care to people in need around the world
Advancing therapies for the prevention of malaria.
Meeting the global challenges of dengue
There is an unmet medical need for dengue fever treatment.
For the investment community
We are committed to serving the best interests of our investors.
Our team is committed to creating innovative, potentially lifesaving medicines to significantly impact the quality of life for those affected by infectious diseases worldwide.
90,000,000+
Cases and 1 Million deaths in the U.S. from COVID-19 infections
627,000
Annual deaths from malaria globally
125,000,000
Travelers to endemic regions per annum
390,000,000
Dengue infections per year
202-327-5422
1025 Connecticut Ave. NW, Suite 1000, Washington, DC 20036